银屑病患者生物治疗可以增加色素痣数量

1 星2 星3 星4 星5 星 (觉着不错就5星评价哦)

银屑病患者色素痣较正常人数量少,最新的研究证实了这一点。但是银屑病患者生物治疗可以增加色素痣数量,本研究发表于 JAAD 10月期上。

研究表明特应性皮炎患者的色素痣数量较少,而且色素痣数量与疾病的严重程度成反比。但是银屑病患者色素痣情况并不清楚。因此为了研究银屑病患者色素痣的数量,以及与疾病严重程度度的关系,进行了此次研究。

研究共调查了189名银屑病患者,对照组同样也有189名。

研究发现,银屑病患者色素痣数量明显要比正常人少,并且体积也要小得多,平均要比正常人小5mm左右。通过排除一些干扰因素,最后发现银屑病患者色素痣数量要比正常少将近3/4。银屑病患者中,10.6%的是先天性色素痣,而正常人中23.3%色素痣是先天性的。

通过生物疗法治疗的中重度银屑病患者,色素痣数量会增加,平均增加35%。

作者认为:「银屑病患者色素痣数量比正常人少可能是免疫在起作用,因此通过免疫疗法可以修复受损的免疫状况」。

但是长期的生物治疗可能增加皮肤癌的可能,因此建议银屑病患者如果采取生物治疗,应注意观察皮肤状况。

Frequency of melanocytic nevi in psoriatic patients is related to treatment and not to disease severity

Background

Few data exist on the relationship between psoriasis and melanocytic lesions.

Objectives

We sought to investigate number of melanocytic nevi in psoriatic patients compared with control subjects and its relationship with disease severity and treatment.

Methods

We performed a prospective study in 189 psoriatic patients and 189 control subjects. Sociodemographic and clinical data were recorded for all participants.

Results

As compared with control subjects, patients had fewer nevi overall [χ2(5) = 52.24, P < .001], fewer nevi less than 5 mm [χ2(4) = 60.28, P < .001], and fewer congenital nevi [χ2(1) = 10.41, P = .002]; no differences in atypical nevi and family history of cancer, including melanoma, were observed. Among psoriatic patients, number of biologics used was a risk factor for a higher nevus count [odds ratio 1.35 (95% CI 1.04-1.76), P = .02] whereas disease severity did not correlate with number of nevi.

Limitations

Low number of psoriatic patients naïve to systemic therapies was a limitation.

Conclusions

Psoriatic patients have fewer nevi than control subjects. Frequency of nevi in psoriatic patients is related to treatment, not to disease severity.

本博客文章如未特别说明,皆默认采用署名-相同方式共享 4.0 国际协议

相关文章

发表评论

电子邮件地址不会被公开。